Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,156.00
Bid: 12,124.00
Ask: 12,128.00
Change: 0.00 (0.00%)
Spread: 4.00 (0.033%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Sterling slips versus dollar; speculators' net long position increases

Mon, 08th Feb 2021 12:25

* Graphic: World FX rates in 2020 http://tmsnrt.rs/2egbfVh

* Graphic: Trade-weighted sterling since Brexit vote http://tmsnrt.rs/2hwV9Hv
(Updates prices, adds comment)

By Elizabeth Howcroft

LONDON, Feb 8 (Reuters) - The pound slipped against a
stronger dollar on Monday, but analysts were bullish about its
outlook and the latest positioning data showed the speculative
long position on the British currency had increased.

The pound has strengthened against both the dollar and euro
in February, boosted by heightened risk appetite in global
markets, optimism surrounding the UK's COVID-19 vaccine rollout
and a lessening of negative rates expectations.

Britain has injected over 12 million first doses of COVID-19
vaccines and is on track to meet a target to vaccinate everyone
in the most vulnerable groups by mid-February.

"Sterling is benefiting mostly from the vaccine race – it’s
really the main differentiator," said Ned Rumpeltin, head of
European currency strategy at TD Securities.

"It’s kind of run out of steam here, just below $1.37," he
said, noting that the pound has struggled to break above that
level since 2018.

At 1206 GMT, the pound was down around 0.4% against a
stronger dollar at $1.3686.

Versus the euro, it was down around 0.2% at 87.92 pence per
euro.

The Bank of England reported the findings of its
consultation with banks about the feasibility of implementing
negative rates last week.

Banks told the BoE that they would need at least six months
to work out how to respond to negative rates - prompting the
pound to rise as investors scaled back any expectations of the
policy being introduced.

Negative rates are "unlikely to happen over the next 6
months due to operational risks, while the need to go negative
after the 6-month period will be rather low as we expect a
strong 2Q economic recovery", ING FX strategists Francesco
Pesole and Petr Krpata wrote in a note to clients.

"Coupled with the fast vaccination, GBP is set to benefit
and GBP/USD to grind slowly higher next week," they said. They
expect cable to move towards $1.50 by the end of the year.

Speculators' net long position on the pound got bigger in
the week to Feb. 2, according to weekly CFTC futures data. The
market has been net bullish on the pound since early December
2020, with the UK's relative success in vaccine
rollouts helping to improve sentiment.

South Africa halted the rollout of AstraZeneca's COVID-19
vaccinations after data showed it gave minimal protection
against mild infection from one variant, but Britain said the
shot still stopped death and serious illness.

(Reporting by Elizabeth Howcroft; editing by Ed Osmond, Larry
King)

More News
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
20 Feb 2024 10:29

AstraZeneca acquires US-based biopharmaceutical company

(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.

Read more
20 Feb 2024 09:40

LONDON BROKER RATINGS: JPMorgan cuts Airtel Africa price target by 28%

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
19 Feb 2024 16:51

LONDON MARKET CLOSE: Europe lacks direction on quiet Monday

(Alliance News) - European markets lacked direction on Monday, after a quiet day as the US markets celebrated George Washington's birthday.

Read more
19 Feb 2024 15:59

London close: Stocks manage gains on globally quiet day

(Sharecast News) - London's financial markets finished in positive territory on Monday, with stocks closing in the green after overcoming minor losses earlier in the session.

Read more
19 Feb 2024 15:39

UPDATE: AstraZeneca completes USD1.1 billion acquisition of Icosavax

(Alliance News) - AstraZeneca PLC on Monday said it has completed the acquisition of Icosavax Inc.

Read more
19 Feb 2024 11:51

LONDON MARKET MIDDAY: Stocks lack direction amid quiet start to week

(Alliance News) - Stock prices in London lacked direction at midday Monday, amid a quiet start to the week.

Read more
19 Feb 2024 08:44

LONDON MARKET OPEN: Stocks drift; Currys surges on takeover interest

(Alliance News) - Stock prices in London were looking for direction early Monday, as investors weighed possible trajectories for US interest rate cuts and a China's economic recovery.

Read more
19 Feb 2024 08:36

TOP NEWS: AstraZeneca celebrates Tagrisso approval and new data

(Alliance News) - AstraZeneca PLC on Monday announced new study data and a new approval for its cancer medication Tagrisso.

Read more
19 Feb 2024 08:03

AstraZeneca's Tagrisso gains FDA approval

(Sharecast News) - Drugmaker AstraZeneca traded higher early on Monday after revealing that a combination of its cancer drug Tagrisso with chemotherapy had gained US approval to treat a particular type of lung cancer.

Read more
19 Feb 2024 07:49

LONDON BRIEFING: MoneySupermarket credits Insurance for growth in 2023

(Alliance News) - Stocks in London are set to fall at Monday's open, as concerns over US inflation trends curb risk appetite, and damp hopes of interest rate cuts from the Federal Reserve.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.